Bosutinib Terminated Phase 4 Trials for Previously Treated PH + CML Treatment

IndicationsStatusPurposePhase
TerminatedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02228382Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors